abacavir 600 mg lamivudine 300 mg

1 INDICATIONS AND USAGE Abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Abacavir and lamivudine tablets, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. (1)

Aurobindo Pharma Limited

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] fatigue` `[3] off label use` `[4] pain` `[5] nausea` `[6] headache` `[7] dyspnoea` `[8] diarrhoea` `[9] arthralgia` `[10] pneumonia`

1 year ago

OVAL ORANGE H 27

1 year ago

H 27 OVAL ORANGE

16 HOW SUPPLIED/STORAGE AND HANDLING

ABACAVIR AND LAMIVUDINE Tablets USP contain 600 mg of abacavir as abacavir sulfate and 300 mg of lamivudine. The tablets are orange colored, modified capsule shaped, film-coated tablets debossed with ‘H’ on one side and ‘27’ on other side. Bottles of 30 NDC 65862-335-30 Cartons of 100 (10 x 10) Unit-dose Tablets NDC 65862-335-10 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

More pills like OVAL H 27

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

abacavir 600 mg lamivudine 300 mg

FDA Reported Adverse Reactions [1] drug ineffective [2] fatigue [3] off label use [4] pain [5] nausea [6] headache [7] dyspnoea [8] diarrhoea [9] arthralgia [10] pneumonia

OVAL ORANGE H 27

H 27 OVAL ORANGE

More pills like OVAL H 27

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] fatigue` `[3] off label use` `[4] pain` `[5] nausea` `[6] headache` `[7] dyspnoea` `[8] diarrhoea` `[9] arthralgia` `[10] pneumonia`